Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$1.99 -11.2%	$1.56	$0.52 ▼ $3.35	$57.31M	1.7	212,319 shs	300,721 shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A
OTLK Outlook Therapeutics	$8.13 -1.9%	$8.61	$4.00 ▼ $40.60	$105.77M	0.04	546,478 shs	263,189 shs
VICL Vical		$1.24	$0.60 ▼ $1.47	$21.01M	0.32	1.44 million shs	35,024 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	+0.90%	-15.79%	+58.84%	+129.72%	+157.47%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
OTLK Outlook Therapeutics	-3.72%	-8.30%	+11.95%	+18.77%	-63.96%
VICL Vical	0.00%	0.00%	0.00%	0.00%	+44.90%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTX Entera Bio	1.7521 of 5 stars	3.5	3.0	0.0	0.0	3.9	0.0	0.0
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	3.0064 of 5 stars	4.4	2.0	0.0	0.0	2.9	1.7	0.6
VICL Vical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	3.00	Buy	$10.00	402.51% Upside
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	471.03% Upside
VICL Vical	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest VICL, NTGN, ENTX, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00
1/25/2024	OTLK Outlook Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$31.40
1/25/2024	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$40.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$130K	440.86	N/A	N/A	$0.36 per share	5.53
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A
VICL Vical	$1.62M	0.00	N/A	N/A	$1.82 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$8.89M	-$0.31	N/A	N/A	N/A	N/A	-101.78%	-83.90%	5/3/2024 (Estimated)
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)
VICL Vical	-$16.25M	-$0.81	N/A	N/A	N/A	-1,002.10%	-29.46%	-27.85%	N/A

Latest VICL, NTGN, ENTX, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/8/2024	Q4 2023	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A
VICL Vical	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	10.32	10.32
NTGN Neon Therapeutics	0.43	1.58	3.00
OTLK Outlook Therapeutics	N/A	0.44	0.44
VICL Vical	N/A	36.84	36.84

Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
NTGN Neon Therapeutics	54.71%
OTLK Outlook Therapeutics	11.20%
VICL Vical	29.06%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	8.90%
NTGN Neon Therapeutics	38.93%
OTLK Outlook Therapeutics	5.30%
VICL Vical	4.58%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	17	28.80 million	26.24 million	Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Optionable
VICL Vical	30	22.84 million	N/A	Not Optionable

VICL, NTGN, ENTX, and OTLK Headlines

Source	Headline
	Evan Gershkovich’s sister was the quiet one. Now she’s his voice. msn.com - March 29 at 9:52 AM
	Video: Travis Kelce’s Friends Attempt to Distract Him in Golf by Playing Taylor Swift’s Song ijr.com - March 29 at 9:52 AM
	Song Suffragettes celebrates 10 years with Wynonna, female country chart-toppers, more msn.com - March 29 at 9:52 AM
	Song lyrics getting simpler, more repetitive, angry and self-obsessed – study theguardian.com - March 29 at 9:52 AM
	Beyoncé’s Younger Daughter Rumi Carter Joins Her on New Song ‘Protector’ msn.com - March 29 at 2:11 AM
	Beyoncé features Shaboozey on her song 'Spaghettii': Who is the hip-hop, country artist? msn.com - March 29 at 2:11 AM
	Creed frontman Scott Stapp on singing his 'life story,' moving to Nashville and finding a dream team msn.com - March 28 at 9:10 PM
	BBC stands by replacing singer with AI-generated voice msn.com - March 28 at 9:10 PM
	Song Lyrics Really Are Getting Simpler and More Repetitive, Study Finds scientificamerican.com - March 28 at 9:10 PM
	Funniest misheard Beyoncé lyrics, from 'Singing lettuce' to 'No bottom knee' msn.com - March 28 at 9:10 PM
	Kanye wife Bianca Censori’s voice heard for first time in newly resurfaced video nydailynews.com - March 28 at 4:10 PM
	Top 'American Idol' and 'The Voice' contestants come from these states: Where Tennessee ranks in the list tennessean.com - March 28 at 4:10 PM
	Song Lyrics Are Now More Repetitive and Simple, Study Confirms msn.com - March 28 at 4:10 PM
	KJP Declares Press Gaggle off the Record as Obama’s Voice Is Heard ijr.com - March 28 at 4:10 PM
	Song lyrics have become angrier since the 80s, study shows msn.com - March 28 at 4:10 PM
	Boston Red Sox minor league pitcher, former Navy standout Noah Song set to undergo Tommy John surgery baltimoresun.com - March 28 at 4:10 PM
	Bachelor Joey Graziadei Reveals the Taylor Swift Song That Reminds Him of New Fiancée Kelsey Anderson msn.com - March 28 at 4:10 PM
	Song Lyrics Are Getting Simpler, More Repetitive: Study barrons.com - March 28 at 4:10 PM
	‘Past Lives’ director Celine Song delivers Pan Asian American Heritage Month keynote speech yaledailynews.com - March 28 at 11:10 AM
	Vampire Weekend Share Video for New Song “Mary Boone”: Watch yahoo.com - March 28 at 11:10 AM
	Fans freak hearing Kanye West’s wife Bianca Censori’s voice for first time in old video msn.com - March 28 at 11:10 AM
	Beyoncé's ‘Cowboy Carter’ tracklist is a puzzle. What we've deciphered so far msn.com - March 28 at 11:10 AM
	Kate Hudson celebrates motherhood in new song 'Live Forever' upi.com - March 28 at 11:10 AM
	This song is our story foxnews.com - March 28 at 11:10 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Entera Bio

NASDAQ:ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Neon Therapeutics

NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Vical

NASDAQ:VICL

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial